ReviewCureus2023
Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Associations between plasma beta amyloid and cognitive decline: A systematic review and meta-analysis.Narra J · 2025Pooled it
- The Brain-Muscle Axis in Neurodegeneration: Linking Dementia, Sarcopenia, and Exercise-Mediated Neuroprotection.International journal of molecular sciences · 2026Review
- Applying ensemble machine learning techniques to MRI scans to predict Alzheimer's disease.Scientific reports · 2026Article
- Exploring Handwriting-Based Biomarkers for Alzheimer's Disease: Identifying Discriminative Features and Tasks to Enhance Diagnostic Accuracy.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnosis of Alzheimer's disease with high accuracy via Petri net modeling of signaling pathways.Scientific reports · 2026Article
- Optimizing Alzheimer's prediction with dental care: comparing robust deep learning models in health and retirement study of America.American journal of neurodegenerative disease · 2026Article
- Pre-analytical characterization of CNS-derived extracellular vesicles from human saliva: effect of room temperature and cellular origin.Frontiers in neuroscience · 2026Article
- Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025Review
- Alzheimer disease predicting from clinical and MRI data using DeepALZNET dual pathway framework.Scientific reports · 2025Article
- A novel approach hybrid of ensemble learning and 3-D CNN mechanism: early-stage diagnosis of Alzheimer's disease using EEG signals.Scientific reports · 2025Article
- AI-Based Severity Classification of Dementia Using Gait Analysis.Sensors (Basel, Switzerland) · 2025Article
- Nanomedicine-Driven Modulation of the Gut-Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer's and Parkinson's Disease.International journal of molecular sciences · 2025Review
- The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer's Disease.Cells · 2025Review
- Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective.International journal of molecular sciences · 2025Review
- Assessment of individual retinal layer thickness and vascular changes in Alzheimer's disease.Scientific reports · 2025Article
- Ensemble Learning-Based Alzheimer's Disease Classification Using Electroencephalogram Signals and Clock Drawing Test Images.Sensors (Basel, Switzerland) · 2025Article
- Early detection of Alzheimer's disease using deep learning methods.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Biological determinants of blood-based biomarker levels in Alzheimer's disease: role of nutrition, inflammation, and metabolic factors.Frontiers in aging neuroscience · 2025Review
- Editorial: Targeting mitochondrial dysfunction for the diagnosis and treatment of Alzheimer's and cognitive-related diseases.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hunt for early Alzheimer's disease detection has created cutting-edge diagnostic instruments with enormous promise. This article examines the many facets of these developments, focusing on how they have revolutionised diagnosis and patient outcomes. These tools make it possible to detect tiny brain changes even before they give birth to clinical symptoms by combining cutting-edge biomarkers, neuroimaging methods, and machine-learning algorithms. A significant opportunity for therapies that can slow the course of the disease exists during this early detection stage. Additionally, these cutting-edge techniques improve diagnostic precision, objectivity, and accessibility. Liquid biopsies and blood-based biomarkers provide non-invasive alternatives, filling accessibility gaps in diagnosis. While issues with standardisation, ethics, and data integration continue, collaboration within research, clinical practice, and policy realms fuels positive developments. As technology advances, the way towards better Alzheimer's diagnosis becomes more evident, giving patients and families dealing with this difficult illness fresh hope. The synergy between scientific advancement and compassionate treatment is crucial for improving Alzheimer's disease diagnosis, as this paper emphasises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.